Skip to main content
Top
Published in: Clinical and Experimental Nephrology 5/2018

01-10-2018 | Images in Nephrology

Renal hemosiderosis with uncontrolled hypertension

Authors: Chang Seong Kim, Sung Sun Kim, Soo Wan Kim

Published in: Clinical and Experimental Nephrology | Issue 5/2018

Login to get access

Excerpt

A 41-year-old man presented with blurred vision, accompanying with severe hypertension. Blood pressure was 240/130 mmHg. Laboratory results were BUN 64.3 mg/dL, creatinine 4.02 mg/dL, hemoglobin 8.9 g/dL, and low haptoglobin 24.9 mg/dL. A kidney biopsy showed marked arterial wall thickening and fibrosis, and heavy brown pigments in proximal and distal tubules. Extensive hemosiderin deposits in the tubular cells were highlighted by Prussian blue iron stain (Fig. 1a, b). The patient was diagnosed as renal hemosiderosis with acute tubular injury and hypertensive arteriosclerosis due to malignant hypertension. Interestingly, heme oxygenase 1 (HO-1) is an inducible enzyme which catabolizes heme, and is upregulated rapidly exposed to heme proteins for cellular protection and adapt heme overload [1]. Accordingly, intensity of HO-1 immunostaining increased within tubules (Fig. 1c). After taking anti-hypertensive medication, serum creatinine was decreased to 2.1 mg/dL and hemoglobin was increased to 11.6 g/dL. His blurred vision was also recovered. …
Metadata
Title
Renal hemosiderosis with uncontrolled hypertension
Authors
Chang Seong Kim
Sung Sun Kim
Soo Wan Kim
Publication date
01-10-2018
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 5/2018
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-018-1546-6

Other articles of this Issue 5/2018

Clinical and Experimental Nephrology 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.